ITGAL and gastric cancer: We examined ITGAL expression in relation to several clinical–pathological parameters in patients, including sample type (healthy/primary tumor), tumor stage (stage 1, 2, 3, and 4), lymph node stage (N0 1, 2, and 3), and gastric cancer subgroup by applying UALCAN.